Soubrie P
Sanofi Recherche, Montpellier, France.
Fundam Clin Pharmacol. 1989;3 Suppl:71s-78s. doi: 10.1111/j.1472-8206.1989.tb00477.x.
The present study aims at reviewing the preclinical evidence suggesting that calcium antagonists exert bio-behavioural effects that may have some relevance to CNS pharmacology, and thus to psychiatry. We briefly address the question of whether calcium antagonists share the following profiles; anxiolytic, antidepressant, neuroleptic, anticonvulsant, analgesic and memory-enhancing. This survey suggests that calcium antagonists and, more especially, dihydropyridine derivatives share all these profiles together. There are, however, important limitations in the interpretation of these preclinical data. Whether the various calcium antagonists may have varying profiles, and thus varying potential psychiatric applications, cannot be explored in depth as there are few comparative data on these drugs on a large variety of animal models. In addition, the doses of calcium antagonists reported to produce behavioural responses are generally higher than the doses sufficient to produce other pharmacodynamic actions. Thus, the possibility that these former responses could be secondary to these latter actions cannot be excluded.
本研究旨在回顾临床前证据,这些证据表明钙拮抗剂具有可能与中枢神经系统药理学相关,进而与精神病学相关的生物行为效应。我们简要探讨钙拮抗剂是否具有以下特性:抗焦虑、抗抑郁、抗精神病、抗惊厥、镇痛和增强记忆。这项调查表明,钙拮抗剂,尤其是二氢吡啶衍生物,共同具有所有这些特性。然而,在解释这些临床前数据时存在重要局限性。由于在大量动物模型上关于这些药物的比较数据很少,所以无法深入探究各种钙拮抗剂是否可能具有不同的特性,以及因此具有不同的潜在精神科应用。此外,据报道产生行为反应的钙拮抗剂剂量通常高于产生其他药效学作用所需的剂量。因此,不能排除这些前者反应可能继发于后者作用的可能性。